MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why GLUE Stock advanced +0.18% Today — RQD Quant Desk Flash
$10.87 +0.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $10.85
Monte Rosa Therapeutics Inc. (GLUE) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $927.4M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $10.85 (-0.16%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-11.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GLUE)Realized 20D OHLCV Swing Band: ±12.1%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY GLUE SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (24% of score)
20D Institutional Volume Accumulation (±12.1% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$10.30-5.4% Next Q
25
Q2 (-2Q)Grade E$9.74+11.3% Next Q
28
Q3 (-1Q)Grade E$10.84+0.3% Next Q
30
CurrentGrade E$10.87-8.9% Hist 90D α
33
Trajectory: E (25) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a GLUE Turnaround Squeeze
While GLUE currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.08) and Max Pain ($11.41) forces dealer call-delta covering toward $27.06.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $GLUE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GLUE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GLUE Stock advanced +0.18% Today — RQD Quant Desk Flash
Monte Rosa Therapeutics Inc. (GLUE) advanced +0.18% to $10.87, trading at 7% of its 52-week range ($9.68 – $25.77). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 7% of its 52-week range ($9.68 – $25.77) with RSI-14 at 44.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.1% around $10.87 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live GLUE Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GLUE)
- ✓Walkthrough of GLUE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GLUE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -43.24%⚡ TESTING RESISTANCE
2026-10-30O $10.85H $11.13L $10.45C $10.87VOL 1.35M
RES: $11.07SUP: $7.43SMA50: $12.08SMA200: $17.38
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GLUE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GLUE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GLUE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GLUE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GLUE)
Health Care Rank #863 of 1016
⚔️ MGTX vs GLUE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (GLUE vs. MGTX, PRME, ODTX, CGEM)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Monte Rosa Therapeutics Inc. (GLUE) ranks #863 by composite RQD confidence (33/100, grade E) and #372 by equity capitalization ($927.4M). Within this direct 5-issuer industry benchmark cohort, GLUE leads on earnings valuation at N/A trailing P/E, while GLUE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with GLUE at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GLUE
ACTIVE
Monte Rosa Therapeutics Inc. | E | 33/100 | — | — | -35.0% | +0.18% | $927.4M | Benchmark Subject |
| MGTX MeiraGTx Holdings plc | E | 27/100 | — | — | -35.0% | -0.46% | $932.1M | /mgtx-vs-glue → |
| PRME Prime Medicine Inc. | E | 21/100 | — | — | -35.0% | -2.24% | $950.4M | /prme-vs-glue → |
| ODTX Odyssey Therapeutics Inc. | C- | 59/100 | — | — | — | +1.48% | $953.0M | /odtx-vs-glue → |
| CGEM Cullinan Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -0.71% | $994.3M | /cgem-vs-glue → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001826457In its most recent audited fiscal period (FY2025, filed 2025-12-31), Monte Rosa Therapeutics Inc. (GLUE) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$38.6M, operating cash flow of -$22.8M, and free cash flow of -$27.5M (-172.3% YoY). On the balance sheet, GLUE closed FY2025 with $448.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$38.6M | -$22.8M | -$27.5M | $448.7M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$72.7M | $42.0M | $38.0M | $438.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$135.4M | -$43.8M | -$43.8M | — | — |
3. GLUE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GLUE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $10.87 (+0.18% 1D, market cap $927.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GLUE ranks #863 in composite RQD confidence.
How does GLUE compare to MGTX and PRME in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GLUE carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MGTX (MeiraGTx Holdings plc) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $932.1M) and PRME (Prime Medicine Inc.) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M). Among the 5-stock peer group, GLUE leads on earnings multiple (N/A) while GLUE leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GLUE?
Per GLUE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001826457), Monte Rosa Therapeutics Inc. generated $0 in revenue, -$38.6M in net income, and -$27.5M in free cash flow against $448.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GLUE trading relative to its 50-day, 200-day, and 52-week technical levels?
GLUE last traded at $10.87 (+0.18% on volume of 1,307,295 shares), positioning the stock -10.02% below its 50-day simple moving average ($12.08) and -37.46% below its 200-day simple moving average ($17.38). Across its 52-week range of $9.68 to $25.77, GLUE sits at the 7.4% percentile with a 14-day RSI of 44.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.1% ($9.55 to $12.19).
GLUE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GLUE stock moving today?
Why GLUE Stock advanced +0.18% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.